biotech investment

Market Access

From roasts to billions: Navigating the biopharma investment...

At BIO-Europe, the session “From Roasts to Billions: Biopharma Investment Landscape” brought together leading voices from investment banking & VC.

R&D

pharmaphorum podcast Episode 203a: Ali Pashazadeh, Treehill

The glimmer of opportunity behind the storm: Ali Pashazadeh ...

Former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, discusses the current ‘perfect storm’ in biotech.

Market Access

Biotech ≠ tech: Why venture capital needs a new playbook for...

Silicon Valley investors have been conditioned by two decades of software: launch quickly, capture users faster, and hit the magic $1 million ARR mark within about three years,1

Market Access

tech bubble network graphic representation in blue and green tones

BIO Boston: 2025 is shaping up to be a year of challenge – b...

What were the major themes to come out of BIO Boston 2025? Despite global events in the background, a fair amount of positivity.

Market Access

Political uncertainties, tariffs, funding crunch? LSX World ...

The weather was hot in London for this year’s LSX World Congress – but what was the atmosphere like at Europe’s leading partnering, strategy, and investment event?

Market Access

Seeing is investing: The power of visuals at every stage of ...

Whether your biotech start-up is in its infancy or on the verge of a major acquisition, how you communicate your work – through clear messaging and impactful visuals – can play a pivotal ro

From roasts to billions: Navigating the biopharma investment...

The glimmer of opportunity behind the storm: Ali Pashazadeh ...

Biotech ≠ tech: Why venture capital needs a new playbook for...

BIO Boston: 2025 is shaping up to be a year of challenge – b...

Political uncertainties, tariffs, funding crunch? LSX World ...

Seeing is investing: The power of visuals at every stage of ...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

biotech investment

Editor's Picks